Article Text

Download PDFPDF
Dupilumab for treating chronic obstructive pulmonary disease

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Key points

  • Dupilumab, a monoclonal antibody that inhibits interleukin-4 and interleukin-13 signalling, is licensed in the UK for a range of conditions including atopic dermatitis and asthma.

  • A placebo-controlled trial assessed the effect of dupilumab in people with chronic obstructive pulmonary disease who had an eosinophil count ≥300 per microlitre and were at an increased risk of an exacerbation.

  • The annualised rate of moderate or severe exacerbations was 0.78 with dupilumab and 1.1 with placebo.

An injection of dupilumab given every 2 weeks for 52 weeks in addition to triple inhaler therapy to people with chronic obstructive pulmonary disease (COPD) who had an eosinophil count ≥300 per microlitre and who were at an increased risk of an exacerbation reduced the annualised rate of moderate or severe exacerbations by 0.32 compared with placebo.1

Overview

An international multicentre phase 3 double-blind randomised controlled trial evaluated the effects of treatment with dupilumab on …

View Full Text

Footnotes

  • Contributors DTB Team.

  • Provenance and peer review Commissioned; internally peer reviewed.